Pharmaceutical Strativa Pharmaceuticals, a unit of Par Pharmaceuticals, announced on Friday that the US Food and Drug Administration had approved Zuplenz (ondansetron) oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. Zuplenz, a unique formulation of ondansetron, is the first oral soluble film approved by the FDA as a prescription medicine, the firm noted. 5 July 2010